290 related articles for article (PubMed ID: 18509003)
1. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
2. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
3. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
5. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
6. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
8. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.
Mitsutake N; Knauf JA; Mitsutake S; Mesa C; Zhang L; Fagin JA
Cancer Res; 2005 Mar; 65(6):2465-73. PubMed ID: 15781663
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
Nikiforova MN; Ciampi R; Salvatore G; Santoro M; Gandhi M; Knauf JA; Thomas GA; Jeremiah S; Bogdanova TI; Tronko MD; Fagin JA; Nikiforov YE
Cancer Lett; 2004 Jun; 209(1):1-6. PubMed ID: 15145515
[TBL] [Abstract][Full Text] [Related]
11. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
[TBL] [Abstract][Full Text] [Related]
12. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
Sheils OM; O'Leary JJ; Sweeney EC
J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
[TBL] [Abstract][Full Text] [Related]
14. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
15. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
Knauf JA; Ma X; Smith EP; Zhang L; Mitsutake N; Liao XH; Refetoff S; Nikiforov YE; Fagin JA
Cancer Res; 2005 May; 65(10):4238-45. PubMed ID: 15899815
[TBL] [Abstract][Full Text] [Related]
16. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS.
Wenzel A; Upadhyay G; Schmitt TL; Loos U
Mol Cell Endocrinol; 2003 Dec; 213(1):99-108. PubMed ID: 15062578
[TBL] [Abstract][Full Text] [Related]
17. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
19. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
20. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
